Contribution of tumor-derived extracellular vesicles in the establishment of the pre-metastatic niche: lessons learned from past experimentations and future directions
Blavier L., Crnjac A., DeClerck YA.
Narrative Review, published in Clin Exp Metastasis (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Clin Exp Metastasis (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41793423
- PMCID
- PMC12967406
- DOI
- 10.1007/s10585-026-10396-z
Abstract (original English)
Tumor-derived extracellular vesicles (TEVs) have been shown to actively contribute to the establishment of the pre-metastatic niche (PMN) through multiple mechanisms of action and the transfer of cargo material to host cells. Here, we report a review of 120 manuscripts published between January 2010 and April 2025 describing observations from in vivo experiments aimed at the examination of the contribution of TEVs to the PMN and the metastatic niche (MN). Whereas most of these publications reported observations made with models of exogenous administration of TEVs prepared in vitro, five publications used endogenous models of TEVs released by implanted tumors to track their fate and examine their role in the PMN. Breast and colon cancers and melanoma are the most common types studied, and lung, liver, bone, and lymph nodes are the most common sites of metastasis examined. Methods to isolate, characterize and label TEVs in exogenous models vary significantly with differential ultracentrifugation (DUC) being the most common method of isolation used, electron microscopy, nano tracking analysis (NTA) and western blotting being used for their characterization, and lipophilic dyes used for labeling. Immunodeficient and immunocompetent mice were used in the majority (94%) with some studies done in zebrafish. Single and multiple administrations of TEVs with doses ranging from 5 to 200 µ
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.